Aligos therapeutics reports fourth quarter and full year 2020 financial results and recent business highlights

- advanced alg-010133 and alg-000184 into the clinic - both expected to generate safety and antiviral activity data in chronic hepatitis b (chb) patients in 2021 - listed on nasdaq global select market under the symbol algs and raised $167.2 million in gross proceeds from the initial public offering (ipo), inclusive of the underwriters' exercise of their overallotment option - cash, cash equivalents and investments of $243.5 million as of december 31, 2020
ALGS Ratings Summary
ALGS Quant Ranking